News | June 15, 2024
Jubilant Pharmova announces voluntary prepayment of US$ 75 million term loan
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
The USFDA has issued 5 observations pursuant to the completion of audit
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
FDA has concluded that this inspection is 'closed'
The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
Based on this inspection and the USFDA VAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP)
The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities
The company will submit an action plan on the observations and will engage with US FDA for next steps.
Subscribe To Our Newsletter & Stay Updated
